Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective of this trial is to evaluate the potential of dalcetrapib to reduce cardiovascular morbidity and mortality in stable CHD patients, with a documented recent ACS.
Critère d'inclusion
- Stable CHD patients, with a documented recent Acute Coronary Syndrome (ACS)